TY - JOUR
T1 - FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice
AU - Li, Jing
AU - Song, Jun
AU - Li, Xian
AU - Rock, Stephanie B.
AU - Sinner, Heather F.
AU - Weiss, Heidi L.
AU - Weiss, Todd
AU - Townsend, Courtney M.
AU - Gao, Tianyan
AU - Evers, B. Mark
N1 - Publisher Copyright:
© 2018 Endocrine Society.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Neurotensin (NT), a 13 amino-acid peptide, is predominantly released from enteroendocrine cells of the small bowel in response to fat ingestion. Free fatty acid receptors (FFARs) FFAR1 and FFAR4 regulate secretion of gut hormones and insulin. Here, we show that docosahexaenoic acid, a longchain fatty acid, has the most dramatic effect on NT release. FFAR1 agonists slightly stimulate and FFAR4 agonists dramatically stimulate and amplify NT secretion. Double knockdown of FFAR1 and FFAR4 decreases NT release, whereas overexpression of FFAR4, but not FFAR1, increases NT release. Administration of cpdA, an FFAR4 agonist, but not TAK-875, a selective FFAR1 agonist, increases plasma NT levels and further increases olive oil-stimulated plasma NT levels. Inhibition of MAPK kinase (MEK)/ERK1/2 decreased fatty acid-stimulated NT release but increased AMP-activated protein kinase (AMPK) phosphorylation. In contrast, inhibition of AMPK further increased NT secretion and ERK1/2 phosphorylation mediated by FFAR1 or FFAR4. Our results indicate that FFAR4 plays a more critical role than FFAR1 in mediation of fat-regulated NT release and in inhibitory crosstalk between MEK/ERK1/2 and AMPK in the control of NT release downstream of FFAR1 and FFAR4.
AB - Neurotensin (NT), a 13 amino-acid peptide, is predominantly released from enteroendocrine cells of the small bowel in response to fat ingestion. Free fatty acid receptors (FFARs) FFAR1 and FFAR4 regulate secretion of gut hormones and insulin. Here, we show that docosahexaenoic acid, a longchain fatty acid, has the most dramatic effect on NT release. FFAR1 agonists slightly stimulate and FFAR4 agonists dramatically stimulate and amplify NT secretion. Double knockdown of FFAR1 and FFAR4 decreases NT release, whereas overexpression of FFAR4, but not FFAR1, increases NT release. Administration of cpdA, an FFAR4 agonist, but not TAK-875, a selective FFAR1 agonist, increases plasma NT levels and further increases olive oil-stimulated plasma NT levels. Inhibition of MAPK kinase (MEK)/ERK1/2 decreased fatty acid-stimulated NT release but increased AMP-activated protein kinase (AMPK) phosphorylation. In contrast, inhibition of AMPK further increased NT secretion and ERK1/2 phosphorylation mediated by FFAR1 or FFAR4. Our results indicate that FFAR4 plays a more critical role than FFAR1 in mediation of fat-regulated NT release and in inhibitory crosstalk between MEK/ERK1/2 and AMPK in the control of NT release downstream of FFAR1 and FFAR4.
UR - http://www.scopus.com/inward/record.url?scp=85050988580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050988580&partnerID=8YFLogxK
U2 - 10.1210/en.2018-00284
DO - 10.1210/en.2018-00284
M3 - Article
C2 - 29796668
AN - SCOPUS:85050988580
SN - 0013-7227
VL - 159
SP - 2939
EP - 2952
JO - Endocrinology
JF - Endocrinology
IS - 8
ER -